Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
MaxCyte Inc - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
MXCT
Nasdaq
3845
https://www.maxcyte.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for MaxCyte Inc
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
- Apr 17th, 2024 8:35 am
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
- Apr 10th, 2024 12:05 pm
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
- Apr 2nd, 2024 12:05 pm
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
- Mar 17th, 2024 8:24 am
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
- Mar 14th, 2024 1:41 pm
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
- Mar 14th, 2024 12:15 pm
MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years
- Mar 13th, 2024 12:40 pm
11 Oversold Healthcare Stocks To Buy Right Now
- Mar 13th, 2024 12:17 pm
MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023
- Mar 12th, 2024 9:31 pm
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
- Mar 12th, 2024 8:05 pm
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
- Mar 4th, 2024 9:05 pm
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
- Feb 9th, 2024 1:05 pm
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
- Jan 30th, 2024 1:05 pm
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
- Jan 23rd, 2024 1:05 pm
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
- Jan 8th, 2024 9:05 pm
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
- Jan 3rd, 2024 1:05 pm
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
- Jan 2nd, 2024 7:00 am
Hedge Funds Say These Penny Stocks Are Poised to Explode
- Dec 19th, 2023 4:21 pm
With 74% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns
- Dec 15th, 2023 10:06 am
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
- Dec 11th, 2023 9:05 pm
Scroll